000			03273nam a22003855i 4500
001			86269
003			ES-MaUEC
005			20230207040550.0
007			cr nn 008mamaa
008			160830s2016 gw | s |||| 0|eng d
020			_a9783319422237
040			_aES-MaUEC
050		4	_aRC271.I45 _bD444 2016
082	0	4	_a614.5999
245	1	0	_aDefects in T Cell Trafficking and Resistance to Cancer Immunotherapy _cedited by Emmanuel Donnadieu
260			_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (VIII, 199 páginas) _b27 ilustraciones, 19 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v9
505	0		_aIntroduction -- Basic rules of T cell migration -- Regulation of anti-tumor T cell migration and function: contribution of real-time imaging -- Vascular normalization, T cell trafficking and anti-tumor immunity -- Disruption of anti-tumor T cell responses by cancer-associated fibroblasts -- Cancer-associated Tertiary Lymphoid Structures, from basic knowledge toward therapeutic target in clinic -- Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy -- Chemokines and T cell trafficking into tumors. Strategies to enhance recruitment of T cells into tumors -- Strategies to enhance migration and persistence of chimeric antigen receptor (CAR)-T cells into tumors.
520	3		_aThis volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy. The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, asignarmaterias , EBSPRINGER
650		7	_aMedicina _0comprobar BNE19900959047 _2embne _9405021
650		7	_aCáncer _xInvestigación _0comprobar BNE19901364217 _2embne _9182523
700	1		_aDonnadieu, Emmanuel _eeditor literario _0Local _999863
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-42223-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319422237
907			_a.b12955474 _b10-10-17 _c21-11-16
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC271.I45 D444 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11597586 _z06-04-17
999			_c86269 _d86269 _x1